Source: Optimi Health
  • Optimi Health Corp. (OPTI) introduces its mushroom supplements to the online Canadian market
  • The company’s functional mushrooms are known for their health benefits
  • The products are available on its website and will be offered in select retailers later this year
  • The company aims to explain the wide uses of functional mushrooms through its simple and easy-to-understand packaging
  • Optimi Health Corp. (OPTI) is down five per cent trading at $0.38 per share as of 11:47 a.m. EST

Optimi Health Corp. (OPTI) is introducing its mushroom supplements to the online Canadian market.

The supplements include Lion’s Mane, Reishi, Turkey Tail, Chaga and Cordyceps.

The company sells a variety of mushroom supplements known for their significant health benefits.

Optimi’s products are available to Canadian consumers on its website and will be offered to select retailers later this year.

Optimi produces the maximum benefits from ingredients through a hot water process using filtered and mineralized water.

Optimi is evolving its line of six mushroom-based supplements and a vegan protein powder featuring an advanced mushroom compound. Each product contains nutrient-dense fungi extracted from the whole fruiting body. In doing so it provides benefits such as stress resistance, immune support, energy, stamina, cognition and focus for enhanced physical and mental well-being.

In December, the company completed building its Princeton facility to allow it to perform onsite assays for its production needs.

 JJ Wilson, Optimi’s board chair, commented

 “With operations set to launch at our Princeton facility, we look forward to ultimately growing and cultivating as many of our own functional mushroom strains as possible to vertically-integrate the company right here in Canada.”

Optimi focuses on adhering to cultivation and extraction methods that preserve the integrity and benefits of the raw material. The company aims to explain the wide uses of functional mushrooms through its simple and easy-to-understand packaging.

Optimi Health Corp. (OPTI) is down five per cent trading at $0.38 per share as of 11:47 a.m. EST.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.